clinical trial · NCT05835180
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Non-alcoholic SteatohepatitisHepatic ImpairmentCirrhosisTVB-2640 - 50 mg
brief summary
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
started
May 1, 2023
primary completion
Dec 18, 2023
completion
Dec 18, 2023
last updated
Dec 26, 2023
official title
A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol